BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36992824)

  • 1. Inversed albumin-to-globulin ratio and underlying liver disease severity as a prognostic factor for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Li J; Li Z; Hao S; Wang J; Chen W; Dai S; Hou Z; Chen B; Zhang Y; Liu D
    Diagn Interv Radiol; 2023 May; 29(3):520-528. PubMed ID: 36992824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative Inversed Albumin-to-Globulin Ratio Predicts Worse Oncologic Prognosis Following Curative Hepatectomy for Hepatocellular Carcinoma.
    Zhang CC; Zhang CW; Xing H; Wang Y; Liang L; Diao YK; Chen TH; Lau WY; Bie P; Chen ZY; Yang T
    Cancer Manag Res; 2020; 12():9929-9939. PubMed ID: 33116850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
    Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
    World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
    Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
    Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.
    Liu X; Li H; Wang F; Su K; He B; He J; Zhong J; Han Y; Li Z
    BMC Gastroenterol; 2023 Sep; 23(1):299. PubMed ID: 37670232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
    Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
    Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy.
    Wu JL; Luo JY; Jiang ZB; Huang SB; Chen GR; Ran HY; Liang QY; Huang MS; Lai LS; Chen JW
    World J Gastroenterol; 2023 May; 29(20):3168-3184. PubMed ID: 37346152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
    Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
    Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
    J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body Composition Changes in Hepatocellular Carcinoma: Prediction of Survival to Transcatheter Arterial Chemoembolization in Combination With Clinical Prognostic Factors.
    Zheng X; Cao F; Qian L; Dong J
    Cancer Control; 2021; 28():10732748211038445. PubMed ID: 34569304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
    Niu XK; He XF
    World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.